RVTY vs TMO vs ILMN Stock Comparison

Revvity, Thermo Fisher Scientific and Illumina Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (TECH) Create a free account to keep reading and compare up to 10 companies.
RVTY Revvity, Inc.
$154.52 +1.5% 1M +65.4% 1Y
Market cap
$16.74B
P/E
66.1x
Revenue (TTM)
$2.94B
Div. yield
0.00%
Life Sciences Tools Healthcare
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$30.16B
P/E
33.7x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
6 wins

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 6 of the 12 questions below (Thermo Fisher Scientific 6, Illumina 6). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRVTYTMOILMNLeader
Larger companyMarket capitalisation $16.74B $256.67B $30.16B TMO
Cheaper on earningsLower P/E, profitable companies only 66.1x 36.3x 33.7x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 29.9x 27.0x 40.9x TMO
Faster revenue growthRevenue growth, trailing twelve months +4.6% +8.3% +5.8% TMO
More profitableNet margin, trailing twelve months 8.6% 14.9% 19.7% ILMN
Better return on capitalReturn on invested capital 3.3% 8.0% 16.6% ILMN
Less leveragedLower net debt / EBITDA 2.6x 3.1x 0.4x ILMN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% TMO
Better 1-year returnPrice return, last 12 months +65.4% +20.7% +72.6% ILMN
Better 5-year returnAnnualised price return, 5 years -3.4%/yr +2.0%/yr -11.1%/yr TMO
Less volatileAnnualised volatility, 1 year 41.2% 30.7% 51.1% TMO
Higher overall scoreMean of the five percentile scores vs peers 61/100 60/100 75/100 ILMN

Percentile Scorecard

RVTYTMOILMN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRVTYTMOILMN
Valuation 72 #70 of 243 62 #94 of 243 63 #91 of 243
Growth 38 #141 of 228 41 #136 of 228 73 #63 of 228
Profitability 81 #43 of 222 82 #40 of 222 98 #5 of 222
Financial Health 56 #110 of 248 31 #172 of 248 57 #107 of 248
Shareholder Returns 56 #70 of 158 82 #29 of 158 85 #25 of 158
Overall 61 60 75
  • RVTY ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRVTYTMOILMNSPY
1 month +1.5%+4.0%-23.8% -2.0%
3 months +32.2%+19.1%+8.4% -2.8%
6 months +64.4%+59.7%+45.2% +2.0%
Year to date +59.7%+20.8%+57.8% +10.6%
1 year +65.4%+20.7%+72.6% +12.2%
3 years +75.9%+52.5%+118.3% +68.1%
3 years, per year +20.7%+15.1%+29.7% +18.9%
5 years -15.8%+10.2%-44.5% +61.4%
5 years, per year -3.4%+2.0%-11.1% +10.1%
10 years +203.6%+362.9%+54.5% +248.5%
10 years, per year +11.7%+16.6%+4.4% +13.3%

Risk

MeasureRVTYTMOILMNSPY
Volatility, 1Y 41.2%30.7%51.1% 13.6%
Downside volatility, 1Y 37.1%29.2%50.9% 13.9%
Beta vs S&P 500, 1Y 1.220.711.11 1.00
Return / volatility, 1Y 1.590.671.42 0.90
Max drawdown, 5Y -59.2%-41.5%-82.9% -25.4%
From 52-week high -6.8%-3.0%-29.5% -3.2%
52-week high $165.78$721.63$293.69 $779.14
52-week low $82.26$438.34$114.44 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRVTYTMOILMN
P/E now vs peer median 68.1xmedian 26.5x 36.6xmedian 26.5x 34.9xmedian 26.5x
P/S now vs peer median 5.9xmedian 2.7x 5.5xmedian 2.7x 6.9xmedian 2.7x
EV/EBITDA now vs peer median 24.4xmedian 18.4x 25.5xmedian 18.4x 25.7xmedian 18.4x
P/FCF now vs peer median 28.7xmedian 25.4x 34.2xmedian 25.4x 29.6xmedian 25.4x
P/B now vs peer median 2.4xmedian 2.5x 4.7xmedian 2.5x 10.0xmedian 2.5x
PEG now vs peer median -2.46median 0.98 4.84median 0.98 0.85median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRVTYTMOILMN
Revenue $2.94B $47.35B $4.54B
Gross profit $1.64B $19.45B $3.08B
Operating income $372.09M $8.47B $960.00M
Net income $253.20M $7.09B $895.00M
Free cash flow $601.13M $7.60B $1.06B
R&D $213.15M $1.40B $975.00M
EPS (diluted) $2.26 $19.06 $5.81
Cash & equivalents $592.80M $5.46B $1.29B
Total debt $2.63B $41.37B $1.79B
Shares (diluted) 111.83M 371.00M 154.00M
Enterprise value $13.35B $233.19B $24.87B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRVTYTMOILMN
P/E 68.1x 36.6x 34.9x
P/FCF 28.7x 34.2x 29.6x
P/Operating cash flow 25.9x 27.8x 25.4x
P/S 5.9x 5.5x 6.9x
P/B 2.4x 4.7x 10.0x
P/Tangible book 3.4x 7.1x 11.4x
EV/EBITDA 24.4x 25.5x 25.7x
EV/EBIT 51.8x 34.8x 33.1x
EV/Revenue 6.6x 6.2x 7.0x
EV/FCF 32.1x 38.8x 30.0x
EV/Operating cash flow 28.9x 31.6x 25.8x
PEG (3Y EPS CAGR) -2.46 4.84 0.85

Growth

14 metrics
MetricRVTYTMOILMN
Revenue growth (1Y) 4.6% 8.3% 5.8%
Revenue CAGR (3Y) 1.7% 2.9% -0.7%
Gross profit growth (1Y) 5.8% 7.8% 8.5%
Gross profit CAGR (3Y) 1.2% 4.0% 4.4%
Operating income growth (1Y) 2.3% 12.8% 23.1%
Operating income CAGR (3Y) 1.0% 7.2% 30.0%
Net income growth (1Y) 6.6% 7.9% 27.5%
Net income CAGR (3Y) -30.1% 6.2% 40.9%
EPS growth (1Y) 10.1% 9.7% 27.5%
EPS CAGR (3Y) -27.6% 7.6% 41.2%
Operating cash flow growth (1Y) 14.4% 21.9% 9.6%
Operating cash flow CAGR (3Y) 49.3% 4.5% 47.5%
Free cash flow growth (1Y) 19.1% 24.3% 5.7%
Free cash flow CAGR (3Y) 44.7% 5.1% 126.5%

Profitability

14 metrics
MetricRVTYTMOILMN
Gross margin 55.9% 41.1% 67.9%
EBITDA margin 26.8% 24.4% 27.3%
Operating margin 12.6% 17.9% 21.2%
Pretax margin 9.6% 16.7% 23.3%
Net margin 8.6% 14.9% 19.7%
FCF margin 20.4% 16.0% 23.3%
Operating cash flow margin 22.7% 19.7% 27.1%
Return on equity 3.5% 13.2% 29.9%
Return on assets 2.2% 6.2% 13.3%
Return on invested capital 3.3% 8.0% 16.6%
Return on capital employed 3.4% 8.5% 17.2%
Asset turnover 0.2x 0.4x 0.7x
Cash conversion (OCF / net income) 2.6x 1.3x 1.4x
Stock comp / revenue 0.9% 0.7% 5.9%

Financial Health

11 metrics
MetricRVTYTMOILMN
Debt / assets 22.9% 36.2% 26.3%
Debt / equity 0.4x 0.8x 0.6x
Net debt / EBITDA 2.6x 3.1x 0.4x
Debt / FCF 4.4x 5.4x 1.7x
Liabilities / assets 36.7% 52.1% 53.8%
Equity / assets 63.3% 47.9% 46.2%
Interest coverage 4.2x 12.0x 9.8x
Current ratio 2.7x 1.8x 2.6x
Quick ratio 1.9x 1.2x 1.8x
Cash ratio 0.8x 0.4x 1.2x
Altman Z-score 3.69 4.18 6.62

Shareholder Returns

7 metrics
MetricRVTYTMOILMN
Dividend yield 0.2% 0.3% –
Net buyback yield 1.5% 1.6% 1.2%
Shareholder yield 1.7% 1.8% 1.2%
Payout ratio (earnings) 12.4% 9.5% –
Payout ratio (FCF) 5.2% 8.9% –
Dividend growth (1Y) -5.9% 8.0% –
Dividend CAGR (3Y) -6.2% 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRVTYTMOILMN
Forward P/E 29.9xFY2026 27.0xFY2026 40.9xFY2026
EPS, next fiscal year $5.16FY2026 $25.92FY2026 $5.06FY2026
EPS growth, next FY +2.0%FY2026 +13.3%FY2026 +4.5%FY2026
EPS growth, the year after +11.0% +2.2% +25.1%
Revenue, next fiscal year $3.00BFY2026 $50.12BFY2026 $4.53BFY2026
Revenue growth, next FY +4.8%FY2026 +12.5%FY2026 +4.4%FY2026
Revenue growth, the year after -2.0% -2.7% +12.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRVTYTMOILMN
Held by institutions 100.0% 90.2% 100.0%
Institutions holding 547 2,627 935
Change in shares held, QoQ -1.3% +0.8% +0.0%
Institutions buying 303 1,145 464
Institutions selling 161 1,145 331
Buyers to sellers 1.88 1.00 1.40

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RVTYTMOILMN
RVTY 1.00 0.72 0.58
TMO 0.72 1.00 0.53
ILMN 0.58 0.53 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RVTY, TMO and ILMN?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Revvity (RVTY) $16.74B, Thermo Fisher Scientific (TMO) $256.67B, Illumina (ILMN) $30.16B.

Which stock is cheaper, RVTY, TMO and ILMN?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Revvity (RVTY) 66.1x, Thermo Fisher Scientific (TMO) 36.3x, Illumina (ILMN) 33.7x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Revvity (RVTY) 29.9x, Thermo Fisher Scientific (TMO) 27.0x, Illumina (ILMN) 40.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Revvity (RVTY) +4.6%, Thermo Fisher Scientific (TMO) +8.3%, Illumina (ILMN) +5.8%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Revvity (RVTY) 8.6%, Thermo Fisher Scientific (TMO) 14.9%, Illumina (ILMN) 19.7%). On return on invested capital, Illumina (ILMN) leads (Revvity (RVTY) 3.3%, Thermo Fisher Scientific (TMO) 8.0%, Illumina (ILMN) 16.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Revvity (RVTY) +65.4%, Thermo Fisher Scientific (TMO) +20.7%, Illumina (ILMN) +72.6%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Revvity (RVTY) -3.4%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Illumina (ILMN) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Thermo Fisher Scientific (TMO) has the highest dividend yield: Revvity (RVTY) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Illumina (ILMN) 0.00%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Revvity (RVTY) 41.2%, Thermo Fisher Scientific (TMO) 30.7%, Illumina (ILMN) 51.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RVTY, TMO and ILMN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.